BioMarin Pharmaceutical Inc. Stock Statistics
Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior. Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average. Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).
| Dates | Signal | Change |
|---|---|---|
| 2023-03-02 - 2023-03-24 | SELL | -9.37 |
| 2023-03-01 - 2023-03-02 | HOLD | -0.86 |
| 2023-02-24 - 2023-03-01 | SELL | -1.06 |
| 2023-02-23 - 2023-02-24 | HOLD | -1.08 |
| 2023-02-22 - 2023-02-23 | SELL | 0.0582 |
Stock Score Effectiveness
Bollinger Stock Signal Effectiveness
Macd Signal Effectiveness
Mv7 Signal Effectiveness
Score signal
Bollinger Signal Statistics
MV signal statistics
MACD Signal Statistics
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
